Page 64 - Merck Sharp News Today

Investegate announcements from SOTIO Biotech, SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Adding pembrolizumab to chemotherapy can improve overall survival in patients with triple-negative breast cancer and high PD-L1 expression.

Health minister says Coalition allowed drugs that can prevent severe cases and hospitalisation to ‘gather dust’ in storage

BERLIN--(BUSINESS WIRE)--Regulatory News:TME Pharma N.V., a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today it has executed a transaction with Atlas Special Opportunities, LLC (ASO), for a total consideration of €3.24...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Orion Corporation (“Orion”) today announced a global development and commercialization agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid ...

/PRNewswire/ -- According to Coherent Market Insights, the global pulmonary drugs market is estimated to be valued at US$ 41.32 billion in 2022 and is expected...

/PRNewswire/ -- According to Coherent Market Insights, the global pulmonary drugs market is estimated to be valued at US$ 41.32 billion in 2022 and is expected...

A review of the past year's most noteworthy developments in international arbitration in Netherlands, including key decisions and legislative changes.

/PRNewswire/ -- According to Coherent Market Insights, the global pulmonary drugs market is estimated to be valued at US$ 41.32 billion in 2022 and is expected...

ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION13 JULY 2022 at 9.00 EEST Orion and MSD announce global collaboration for the development and commercialisation of ODM-208